The class action concerns whether GoodRx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ: GDRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged ...

It's also worth mentioning that both stocks have a bit of short squeeze potential. Short interest represents 10.8% of GDRX's available float, and 9.3% of BMBL's. Bumble stock isn't making any particularly outsized moves today, up 0.2% at $11.99. However, the stock is on a notable uptrend after its May 8 record low of $9.83. BMBL jumped broke above several short-term moving averages following this trough, including former pressure at the 60-day trendline. This week in Cheap Seats: Stocks Under $20 segment, w ...

RADNOR, Pa., May 15, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against GoodRx Holdings, Inc. (NASDAQ: GDRX) ("GoodRx" or the "Company") on behalf of investors who purchased or acquired GoodRx common stock between September 23, 2020, and November 8, 2022, inclusive (the "Class Period"). This action, captioned Barsuli v. GoodRx Holdings, Inc., et al., Case No. Case 2:24-cv-03282- DDP-AJR was filed i ...

GoodRx Holdings, Inc. (GDRX) reported $197.88 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 7.6%. EPS of $0.08 for the same period compares to $0.07 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $196.2 million, representing a surprise of +0.86%. The company delivered an EPS surprise of -11.11%, with the consensus EPS estimate being $0.09.While investors closely watch year-over-year changes in headline numbers -- revenue and earni ...

GoodRx Holdings, Inc. (NASDAQ:GDRX) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Whitney Notaro - VP, IR Scott Wagner - Interim CEO Karsten Voermann - CFO Conference Call Participants Michael Cherny - Leerink Partners Jailendra Singh - Truist Securities Stephanie Davis - Barclays Daniel Grosslight - Citi Lisa Gill - JP Morgan Charles Rhyee - TD Cowen Stan Bernstein - Wells Fargo Securities Scott Schoenhaus - KeyBanc Sean Dodge - RBC Capital Markets John Ransom - RJF John Park ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________ FORM 10-Q ________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-39549 ________________________ ...

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.08, delivering no surprise.Over the last four quarters, the company ha ...

Exhibit 99.1 GOODRX REPORTS FIRST QUARTER 2024 RESULTS SANTA MONICA, Calif. -- (May 9, 2024) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading destination for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights Exhibit 99.1 Revenue and Adjusted Revenue increased 8% to $197.9 million compared to $184.0 million. Prescription transactions revenue increased 8% to $145.4 million compar ...

GoodRx Holdings Inc (NASDAQ:GDRX) stock is up 1.9% to trade at $6.87 this morning, after Keybanc upgraded the digital healthcare service to "overweight" from "sector weight," while setting a price target of $9. The analyst in coverage cited the potential for strong subscriber growth, as well as a positive shift in the company's monthly active users (MAUs). GoodRx  jumped nearly 4% premarket, but broad market headwinds are capping gains. The stock has support at its 80-day moving average, which has propped u ...

GoodRx Holdings, Inc. (GDRX) closed the last trading session at $6.77, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.74 indicates a 29.1% upside potential.The mean estimate comprises 17 short-term price targets with a standard deviation of $2.19. While the lowest estimate of $5 indicates a 26.1% decline from the current price level, the most optimistic analyst exp ...